| RA patients (n = 23) |
---|---|
Demographics | |
 Age, years | 52.6 (2.8)* |
 Gender, % female | 77 |
Clinical characteristics | Â |
 Disease duration, years | 4.7 (1) |
 Rheumatoid factor and/or anti-CCP positive, % | 30 |
 Disease activity score in 28 joints | 6 (0.2) |
 Swollen (28) | 8.7 (1.2) |
 Tender (28) | 10.8 (1.7) |
 C-reactive protein, mg/dL | 2.4 (1.3) |
 Erythrocyte sedimentation rate, mm/h | 39.8 (7.3) |
Treatments | |
 Naïve to treatment, n/total (%) | 13/23 (56 %) |
 Methotrexate, n/total (%) | 7/23 (30) |
 Methotrexate dose, mg/week | 17.1 (1.5) |
 Leflunomide, n/total (%) | 3/23 (13) |
 Biologic agents, n/total (%) | 4/23 (17) |
 Glucocorticoids, n/total (%) | 5/23 (22) |
 Glucocorticoid dose, mg/day | 8.2 (3.3) |